Lawson Health Research Institute

Urology Care Foundation Announces 2024 Research Awards of Distinction

Retrieved on: 
Thursday, April 4, 2024
Western University, Research, American Urological Association, Xenobiotic, Translational research, Postdoctoral researcher, Prostate cancer, Environment, Lawson Health Research Institute, Immunology, Committee, Gut microbiota, University, Macrophage, Doctor of Philosophy, Role, Publication, Pediatrics, University of California, Pediatric urology, Division, FACS, Radiation therapy, Society, Michigan Medicine, Nursing

BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.

Key Points: 
  • BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.
  • "We are optimistic about the future of urologic research with the selection of the recipients of this year’s Urology Care Foundation Research Awards,” said Harris M. Nagler, MD, Urology Care Foundation President.
  • “We are thrilled with the Urology Care Foundation Research Awards of Distinction awardees this year,” said Steven Kaplan, MD, Chair of the AUA’s Research Council.
  • The awardees will be celebrated at the Urology Care Foundation Research Honors Program held at the AUA Annual Meeting in May 2024.

Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test

Retrieved on: 
Monday, November 6, 2023
FDA, Physical examination, US, Biomarker, Therapy, SARS-CoV-2, Hospice and palliative medicine, Economics, London Health Sciences Centre, Treatment, Lawson Health Research Institute, Intellectual property, Doctor of Philosophy, Research, CSE, Critical care, Quality of life, Chest pain, CDC, COVID-19, COVID, Disorder, Medicine, Lawson, Arrhythmia, Brain, Western University, RVV, Western, Diagnosis, Harvard University, Infection, Fatigue, Pharmaceutical industry, Revive

TORONTO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, newly-formed subsidiary, Revive Diagnostics Inc., today announced that it has entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to novel blood biomarkers that characterize long COVID. The discovery of the biomarkers identified by a research team at Lawson, led by Dr. Douglas Fraser, was recently published in the journal, Molecular Medicine1. 

Key Points: 
  • Currently, there is no FDA-approved clinical diagnosis of long COVID and it is estimated to occur in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
  • Revive Therapeutics and Lawson will work together in completing the development of a qELISA laboratory test kit and a lateral flow assay point of care device for rapid testing of long COVID.
  • In addition, Revive Therapeutics will evaluate the potential of the long COVID test as a companion to Bucillamine – a potential treatment for long COVID disease.
  • Under the terms of the agreement, Revive Diagnostics Inc., a subsidiary of Revive Therapeutics, has gained exclusive worldwide rights to intellectual property for the development and commercialization of novel blood biomarkers that characterize long COVID disease.

Cubresa Installs First BrainPET Insert System at Lawson Health Research Institute

Retrieved on: 
Tuesday, May 30, 2023
Science, Other Science, Radiology, Oncology, Health, Medical Devices, Hospitals, Health Technology, Partnership, Ageing, PET, Lawson Health Research Institute, Brain, Research, DSM-IV codes, Google Images, Dementia, Lawson, Diagnosis, Medical imaging

Cubresa has installed the first BrainPET Insert System at St. Joseph’s Health Care London, in partnership with the hospital’s research institute – Lawson Health Research Institute.

Key Points: 
  • Cubresa has installed the first BrainPET Insert System at St. Joseph’s Health Care London, in partnership with the hospital’s research institute – Lawson Health Research Institute.
  • The Cubresa BrainPET is a removeable, high-performing PET scanner, specifically designed for PET/MRI brain imaging.
  • “We are very excited to receive the world’s first Cubresa BrainPET.
  • By operating inside of our existing 3T MRI, this head-only PET system will enhance the possibilities of brain imaging with superior image resolution,” said Dr. Jonathan Thiessen, Imaging Scientist at Lawson Health Research Institute.

QMC Health Inc. Obtains Exclusive Rights to Novel Long COVID Biomarkers in Development of High Sensitivity Long COVID Rapid Test

Retrieved on: 
Tuesday, November 1, 2022
COVID-19, EMA, Population, Adult, CEO, Critical care, Health, Western, COVID, Western University, Doctor of Philosophy, Partnership, Biomarker, Research, GLOBE, Nano, Intellectual property, Economics, Patent, Technology, Private Securities Litigation Reform Act, FDA, Lawson Health Research Institute, Patient, Medicine, QDX, CDC, Squire, Forward-looking statement, Harvard University, London Health Sciences Centre, Jean-Louis Vincent, Science, Diagnosis, Medical imaging, Pharmaceutical industry, Long COVID, Sepsis

AUSTIN, TX, Nov. 01, 2022 (GLOBE NEWSWIRE) -- QMC Health Incorporated announced today an agreement with Lawson Health Research Institute for the exclusive rights to novel blood biomarkers that characterize Long COVID disease. The discovery of the biomarkers identified by a research team at Lawson, led by Dr. Douglas Fraser, was recently published in the journal, Molecular Medicine1. QMC Health will use these biomarkers to develop a Long COVID point-of-care rapid test based on its QDX™ HPFIS (High-Performance Fluorescent Immuno-Sensors) for high sensitivity bio-detection and quantification to develop a best-in-class, low-cost rapid diagnostic testing assay platform.

Key Points: 
  • AUSTIN, TX, Nov. 01, 2022 (GLOBE NEWSWIRE) -- QMC Health Incorporated announced today an agreement with Lawson Health Research Institute for the exclusive rights to novel blood biomarkers that characterize Long COVID disease.
  • QMC Health will use these biomarkers to develop a Long COVID point-of-care rapid test based on its QDX HPFIS (High-Performance Fluorescent Immuno-Sensors) for high sensitivity bio-detection and quantification to develop a best-in-class, low-cost rapid diagnostic testing assay platform.
  • With the Long COVID biomarkers from Lawson, we believe QMC Health is well-positioned to develop an accurate and rapid Long COVID point of care test, said Stephen Squires, President, and CEO of QMC Health Inc. Long-Covid is a multisystemic disease that involves many organs and presents a wide range of symptoms.
  • "The QDX HPFIS platform delivers a low-cost rapid test with high sensitivity and multiplex capabilities not previously found in a lateral flow test format.

Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

Retrieved on: 
Thursday, July 21, 2022
DNA, Hospital das Clínicas, Metabolomics, Knowledge, Catapult, Ministry of Economy (Spain), GLOBE, Innovation, Large-cell lung carcinoma, ACHL, Industry, Research, Plants for Human Health Institute, Laboratory, Innovate UK, Science and technology in Asia, Valencian Community, UK Research and Innovation, Solution, Gene, Intention, Institute, Lawson Health Research Institute, Therapy, NASDAQ, Hospital, University, Competition (economics), Cell, Ministry, UKRI, EVP, NSCLC, Company, Patient, Fundacion NYC, Goal, Program, University of Hanover, Engineering, Growth, Education, European, Pharmaceutical industry, EU, Technology

We are thrilled to be part of this consortium to support the continued innovation of cell therapy manufacturing processes, said Edward Samuel, EVP, Technical Operations at Achilles Therapeutics.

Key Points: 
  • We are thrilled to be part of this consortium to support the continued innovation of cell therapy manufacturing processes, said Edward Samuel, EVP, Technical Operations at Achilles Therapeutics.
  • Most cell therapy manufacturing platforms do not provide sufficient real-time data during production which can limit proactive decision making and reduce overall scalability.
  • This consortium will collaborate on the development of a proof-of-concept, first-in-class, smart bioprocessing manufacturing platform for personalized cell therapies that aims to incorporate advanced inline spectroscopic sensors and smart machine-learning process control systems.
  • The project, named SMARTER, will be conducted by a team of world-leading, interdisciplinary scientists from the consortium with expertise in cancer immunotherapy, bioinformatics, cell therapy bioprocess engineering, metabolomics and advanced sensor development.

Lawson Health Research Institute Selects Cubresa’s BrainPET System to Support Neurological Research Studies

Retrieved on: 
Monday, May 2, 2022
Medical Devices, Health, Other Health, Other Science, Radiology, Science, Neurodegeneration, Innovation, Lawson, Epilepsy, Canada Foundation for Innovation, Diffusion, MRI, Neuroinflammation, Dementia, University, Lawson Health Research Institute, CFI, Diagnosis, Lists of diseases, Hospital, Intellectual disability, Movement disorders, Brain damage, Sale, Brain, CEO, Cognitive reserve, Multimedia, PET, Medical imaging

Lawson Health Research Institute has selected Cubresas investigational BrainPET system to add to their suite of imaging tools.

Key Points: 
  • Lawson Health Research Institute has selected Cubresas investigational BrainPET system to add to their suite of imaging tools.
  • (Photo: Business Wire)
    The BrainPET scanner will be used to support neurological research studies at Lawson in three specific areas.
  • Cubresa has a long-standing relationship with Lawson Health Research Institute and is pleased to continue supporting their novel neurodegenerative research programs with our BrainPET system, said Dr. James Schellenberg, Cubresas Founder and CEO.
  • Lawson has joined Cubresas Foundational BrainPET Client Program and we look forward to working with them over the coming years.

Canadian Cancer Society to lead nation in cancer prevention and survivorship work with new innovation hub

Retrieved on: 
Wednesday, November 10, 2021
Family, Canadian Cancer Society, Adoption, Center, Cancer, Leukemia, Lower Mainland, Industry, Abbotsford Regional Hospital and Cancer Centre, MLA, Government, Organization, CEO, Survivor, Disease, CCS, Lawson Health Research Institute, COVID-19, Research, CCPS, Canadian Institutes of Health Research, Policy, University Health Network, Partnership, Human, American Cancer Society, Mental health, Awareness, Solution, Strathcona County, EN, Princess Margaret Hospital, Princess, Environment, Climate change, Patient, Life, Public, Leukemia & Lymphoma Society of Canada, Progress, Dietary supplement, Pharmaceutical industry, Birth control, Medical device

Through the Centre, CCS will augment funding for cancer prevention and survivorship research, bring researchers together, and connect them with the people and organizations that can bring research to life.

Key Points: 
  • Through the Centre, CCS will augment funding for cancer prevention and survivorship research, bring researchers together, and connect them with the people and organizations that can bring research to life.
  • This will give Canadians improved access to new cancer prevention and support programs that improve their physical and mental health.
  • As the voice for Canadians who care about cancer, we work with governments to establish health policies to prevent cancer and better support those living with the disease.
  • No other organization does all that we do to improve lives today and to change the future of cancer forever.

Biotech Support Group & Lawson Health Research Institute Enter Collaborative Research Agreement to Monitor Protease Inhibitor Function During Covid-19 Infections

Retrieved on: 
Tuesday, September 28, 2021
Blood, Peptide, ASMS, Goal, Business development, Partnership, Ingo Nugel, Robarts Research Institute, Research, Protein, Mass spectrometry, Patient, Protease, Risk, Partner, LC-MS, Lawson Health Research Institute, Infection, Inflammation, Health, Immunity, Society, Conference, Doctor of Philosophy, Cancer, COVID-19, Poster, Immunoglobulin G, Coagulation, MD, Western University, Biomarker, Business, Method, BSG, Medicine, Proteomics, Growth, Digestion, Disease, Type, Science, Founder, Severe acute respiratory syndrome coronavirus 2, Thrombosis, Lawson, Hospital, Degenerative disease, Enzyme, Intellectual property, Industry, American Society for Mass Spectrometry, Pharmaceutical industry, Vaccine

MONMOUTH JUNCTION, N.J. and LONDON, Ontario, Sept. 28, 2021 /PRNewswire-PRWeb/ -- Biotech Support Group and Lawson Health Research Institute announce a collaborative research agreement.

Key Points: 
  • MONMOUTH JUNCTION, N.J. and LONDON, Ontario, Sept. 28, 2021 /PRNewswire-PRWeb/ -- Biotech Support Group and Lawson Health Research Institute announce a collaborative research agreement.
  • The agreement supports further research to monitor protease inhibitor function acquired from blood collected from hospitalized patients with the SARS-CoV-2 (COVID-19) virus.
  • Lawson Health Research Institute is one of Canada's top hospital-based research institutes, tackling the most pressing challenges in health care.
  • As the research institute of London Health Sciences Centre and St. Joseph's Health Care London, our innovation happens where care is delivered.

Simple medical device improves care after kidney transplantation

Retrieved on: 
Tuesday, June 1, 2021
Anatomy, Medicine, Branches of biology, Kidney transplantation, Organ transplantation, Lawson Health Research Institute, Artificial kidney, Kidney

LONDON, June 1, 2021 /PRNewswire/ -- In a published study , a team from Lawson Health Research Institute (LHSC), in Ontario Canada, has found that a simple medical device can reduce swelling after kidney transplantation.

Key Points: 
  • LONDON, June 1, 2021 /PRNewswire/ -- In a published study , a team from Lawson Health Research Institute (LHSC), in Ontario Canada, has found that a simple medical device can reduce swelling after kidney transplantation.
  • Patients using the device following kidney transplantation experienced shorter hospital stays and reduced surgical site infections by nearly 60 per cent.
  • The geko device has been adopted into the care pathway and is now being offered to patients at LHSC in recovery after receiving a new kidney.
  • "My surgeon explained in very simple terms that it was as if my new kidney wasn't awake yet," describes Garcia.